Whether you embrace Braak, Borghammer or not, this image from Poewe, Lang and others in nature Nature Reviews Disease Primers 2017 is a single wonderful Parkinson teaching tool. nature.com/articles/nrdp2… #parkinson

Report finds "a high level of acceptability of the MoveONParkinson digital solution, serving as a foundation for assessing its impact on exercise engagement &, subsequently, its influence on symptom management & quality of life of people with #Parkinsons" frontiersin.org/journals/publi…

New research supports "exploration of whether Acetyl-DL-leucine may have disease-modifying properties in prodromal #Parkinsons"; 2 case studies of REM sleep behaviour disorder; 3 weeks ADLL-treatment=RBD-SS-3⬇️in both & remains⬇️for >18 months of treatment nature.com/articles/s4146…

Researchers compare α-synuclein oligomers & synaptic density in the skin biopsies from 27 cases of GBA1-associated #Parkinson's disease & 36 individuals with idiopathic PD (+ 28 controls); PLA score & synaptic density distinguish GBA1-PD from iPD onlinelibrary.wiley.com/doi/10.1111/bp…

Calbindin & Girk2/Aldh1a1 (nigrosome) define resilient vs vulnerable dopaminergic neurons in a primate #Parkinsons (MPTP) model nature.com/articles/s4153…

Ginsenoside Rg1, a key component of ginseng, rescues mouse model of #Parkinsons by eliminating stress-induced accumulation of RTP801 & α-synuclein autophagic degradation blockade nature.com/articles/s4140…

D&D Pharmatech receives the nod from the U.S. FDA to conduct a Phase 2 clinical trial of their GLP-1R agonist NLY01 in 240 patients with #MultipleSclerosis; 96 weeks of treatment koreabiomed.com/news/articleVi…

Suppression of the JAK/STAT pathway (using AZD1480) results in inhibition of neuroinflammation in the line 61-PFF mouse model of #Parkinsons jneuroinflammation.biomedcentral.com/articles/10.11…

Researchers from Merck present the discovery & optimization of a “reinvented” indazole series (N-Heteroaryl Indazole) of LRRK2 inhibitors; This is a new class of agents being developed for #Parkinsons pubs.acs.org/doi/10.1021/ac…

A new meta-analysis explores the association between metabolic syndrome & the risk of #Parkinsons; It finds that the presence of metabolic syndrome & its individual components may act as potential risk factors bmcneurol.biomedcentral.com/articles/10.11…

Rune Labs RuneLabsCEO introduce new "StrivePD-AI" Generative artificial intelligence clinical reports that provide a comprehensive, monthly outlook of disease progression along with personalized educational content to help with care plans businesswire.com/news/home/2024…

Allyx Therapeutics Allyx Therapeutics announces that the 1st patient has been dosed in the Phase 1 clinical trial of their candidate 'ALX-001' (previously BMS-984923) - a silent allosteric modulator of mGluR5 being developed for #Parkinsons globenewswire.com/news-release/2…

Want to get involved with #Parkinsons research, but scared about getting too involved? Do something simple, like a survey:

Missed this: Denali Therapeutics Denali Therapeutics plans to initiate a global Phase 2a study in 2024 to evaluate safety & biomarkers associated with their LRRK2 inhibitor BIIB122 in participants with #Parkinsons disease & confirmed pathogenic variants of LRRK2 investors.denalitherapeutics.com/news-releases/…

New clinical trial registered: Ventyx Biosciences has registered a Phase 2a study for their oral, CNS-penetrant NLRP3 inhibitor VTX3232 in early-stage #Parkinsons; This will be a 28-day open label study, involving 10 participants clinicaltrials.gov/study/NCT06556…

New clinical trial registered: Prevail Therapeutics (Eli Lilly and Company) initiates a new Phase 1 SAD & MAD clinical trial in healthy volunteers & people with #Parkinsons to evaluate an intrathecally delivered siRNA targeting α-synuclein mRNA, called LY3962681 clinicaltrials.gov/study/NCT06565…

Researchers conducted a double-blind randomized, controlled study (N=35) to assess if 48 Hz cerebellar repetitive transcranial magnetic stimulation results in improved motor function in #Parkinsons; 2x/day on 5 consecutive days; Gait=better 1 month later onlinelibrary.wiley.com/doi/10.1002/ac…

Researchers looked at the relationships of B12 & homocysteine with outcomes in the SURE-PD, SURE-PD3, & STEADY-PDIII clinical trials in #Parkinsons; Initiation of L-dopa associated with⬆️Hcy in those not taking B12 supplement; B12 intake higher overall content.iospress.com/articles/journ…